Pharmacotherapy for post-stroke aphasia: what are the options?

References

• Kiran S, Thompson CK. Neuroplasticity of language networks in aphasia: advances, updates, and future challenges. Front Neurol. 2019;10. doi: 10.3389/FNEUR.2019.00295
   Web of Science ®Google Scholar
• Pedersen PM, Stig Jørgensen H, Nakayama H, et al. Aphasia in acute stroke: incidence, determinants, and recovery. Ann Neurol. 1995;38(4):659–666. doi: 10.1002/ANA.410380416
   PubMed Web of Science ®Google Scholar
• Hinman JD, Rost NS, Leung TW, et al. Principles of precision medicine in stroke. J Neurol Neurosurg Psychiatry. 2017;88(1):54–61. doi: 10.1136/JNNP-2016-314587
   PubMed Web of Science ®Google Scholar
• Harvey SR, Carragher M, Dickey MW, et al. Treatment dose in post-stroke aphasia: a systematic scoping review. Neuropsychological Rehabilitation. 2021;31(10):1629–1660. doi: 10.1080/09602011.2020.1786412
   PubMed Web of Science ®Google Scholar
• Brady MC. Dosage, intensity, and frequency of language therapy for aphasia: a systematic review-based, individual participant data network meta-analysis. Stroke. 2022;53:956–967.
   PubMed Web of Science ®Google Scholar
• Brady MC, Ali M, VandenBerg K, et al. Precision rehabilitation for aphasia by patient age, sex, aphasia severity, and time since stroke? A prespecified, systematic review-based, individual participant data, network, subgroup meta-analysis. Int J Stroke. 2022;17(10):1067–1077. doi: 10.1177/17474930221097477
   PubMed Web of Science ®Google Scholar
• Wallace SJ, Worrall L, Rose T, et al. A core outcome set for aphasia treatment research: the ROMA consensus statement. Int J Stroke. 2019;14(2):180–185. doi: 10.1177/1747493018806200
   PubMed Web of Science ®Google Scholar
• Zhang X, Shu B, Zhang D, et al. The efficacy and safety of pharmacological treatments for post-stroke aphasia. CNS Neurol Disord Drug Targets. 2018;17(7):509–521. doi: 10.2174/1871527317666180706143051
   PubMed Web of Science ®Google Scholar
• Saxena S, Hillis AE. An update on medications and noninvasive brain stimulation to augment language rehabilitation in post-stroke aphasia. Expert Rev Neurother. 2017;17(11):1091–1107.
   PubMed Web of Science ®Google Scholar
• Berthier ML. Ten Key reasons for continuing research on pharmacotherapy for post-stroke aphasia. Aphasiology. 2021;35(6):824–858. doi: 10.1080/02687038.2020.1769987
   Web of Science ®Google Scholar
• Cichon N, Wlodarczyk L, Saluk-Bijak J, et al. 2021. Novel advances to post-stroke aphasia pharmacology and rehabilitation; J clin medVol. 10. doi: 10.3390/JCM10173778
   Google Scholar
• Katsari M, Angelopoulou G, Laskaris N, et al. Common neuroanatomical substrate of cholinergic pathways and language-related brain regions as an explanatory framework for evaluating the efficacy of cholinergic pharmacotherapy in post-stroke aphasia: a review. Brain Sci. 2022;12(10):1273. doi: 10.3390/brainsci12101273
   PubMed Web of Science ®Google Scholar
• Picano C, Quadrini A, Pisano F, et al. Adjunctive approaches to aphasia rehabilitation: a review on efficacy and safety. Brain Sci. 2021;11(1):1–29.
   Web of Science ®Google Scholar
• Sheppard SM, Sebastian R. Diagnosing and managing post-stroke aphasia. Expert Rev Neurother. 2021;21(2):221–234.
   PubMed Web of Science ®Google Scholar
• Vitti E, Hillis AE. Treatment of post-stroke aphasia: a narrative review for stroke neurologists. Int J Stroke. 2021;16(9):1002–1008.
   PubMed Web of Science ®Google Scholar
• Capizzi AN, Woo JE, Magat E. Poststroke aphasia treatment: a review of pharmacologic therapies and noninvasive brain stimulation techniques. J Int Soc Phys Rehabil Med. 2022;5(1):1.
   Google Scholar
• Basilakos A, Hula WD, Johnson LP, et al. Defining the neurobiological mechanisms of action in aphasia therapies: applying the rehabilitation treatment specification system framework to research and practice in aphasia. Arch Phys Med Rehabil. 2022;103(3):581–589. doi: 10.1016/J.APMR.2021.10.017
   PubMed Web of Science ®Google Scholar
• Berthier ML, Edelkraut L, López-González FJ, et al. Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: a feasibility study. Brain Lang. 2023;236:105205.
   PubMed Web of Science ®Google Scholar
• Berthier ML. Poststroke aphasia: epidemiology, pathophysiology and treatment. Drugs Aging. 2005;22(2):163–182.
   PubMed Web of Science ®Google Scholar
• Berthier ML, Green C, Lara JP, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65(5):577–585. doi: 10.1002/ana.21597
   PubMed Web of Science ®Google Scholar
• Albert ML, Bachman DL, Morgan A, et al. Pharmacotherapy for aphasia. Neurology. 1988;38(6):877–877.
   PubMed Web of Science ®Google Scholar
• De Deyn PP, De Reuck J, Deberdt W, et al. Treatment of acute ischemic stroke with piracetam. Stroke. 1997;28(12):2347–2352. doi: 10.1161/01.STR.28.12.2347
   PubMed Web of Science ®Google Scholar
• Enderby P, Broeckx J, Hospers W, et al. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin Neuropharmacol. 1994;17(4):320–331. doi: 10.1097/00002826-199408000-00003
   PubMed Web of Science ®Google Scholar
• Huber W, Willmes K, Poeck K, et al. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch Phys Med Rehabil. 1997;78(3):245–250. doi: 10.1016/S0003-9993(97)90028-9
   PubMed Web of Science ®Google Scholar
• Kristinsson S, den Ouden DB, Rorden C, et al. Predictors of therapy response in chronic aphasia: building a foundation for personalized aphasia Therapy. J Stroke. 2022;24(2):189–206. doi: 10.5853/jos.2022.01102
   PubMed Web of Science ®Google Scholar
• Cramer SC, Wolf SL, Saver JL, et al. The utility of domain-specific end points in acute stroke trials. Stroke. 2021;52(3):1154–1161. doi: 10.1161/STROKEAHA.120.031939
   PubMed Web of Science ®Google Scholar
• Neuberger A, Oraiopoulos N, Drakeman DL. Renovation as innovation: is repurposing the future of drug discovery research? Drug Discov Today. 2019;24(1):1–3.
   PubMed Web of Science ®Google Scholar
• Clout AE, Della Pasqua O, Hanna MG, et al. Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. J Neurol Neurosurg Psychiatry. 2019;90(11):1270–1275. doi: 10.1136/JNNP-2019-320879
   PubMed Web of Science ®Google Scholar
• Barrett AM, Levy CE, Gonzalez Rothi LJ. Pharmaceuticals for poststroke and brain injury rehabilitation. Am J Phys Med Rehabil. 2007;86(8):603–604.
   PubMed Web of Science ®Google Scholar
• Engelter ST, Urscheler N, Baronti F, et al. Frequency and determinants of using pharmacological enhancement in the clinical practice of in-hospital stroke rehabilitation. Eur Neurol. 2012;68(1):28–33. doi: 10.1159/000335895
   PubMed Web of Science ®Google Scholar
• Berthier ML, Dávila G, Green-Heredia C, et al. Massed sentence repetition training can augment and speed up recovery of speech production deficits in patients with chronic conduction aphasia receiving donepezil treatment. Aphasiology. 2014;28(2):188–218. doi: 10.1080/02687038.2013.861057
   Web of Science ®Google Scholar
• Ghosh D, Sehgal K, Sodnar B, et al. Drug repurposing for stroke intervention. Drug Discov Today. 2022;27(7):1974–1982. doi: 10.1016/J.DRUDIS.2022.03.003
   PubMed Web of Science ®Google Scholar
• Spellicy SE, Hess DC. Recycled translation: repurposing drugs for stroke. Transl Stroke Res. 2022;13(6):866–880.
   PubMed Web of Science ®Google Scholar
• Sajid N, Friston KJ, Ekert JO, et al. 2020. Neuromodulatory control and language recovery in bilingual aphasia: an active inference approach. Behav Sci; (Basel, Switzerland). doi: 10.3390/BS10100161
   Google Scholar
• De Kloet SF, Mansvelder HD, De Vries TJ. Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors. Biochem Pharmacol. 2015;97(4):425–438.
   PubMed Web of Science ®Google Scholar
• Mena-Segovia J, Bolam JP. Rethinking the pedunculopontine nucleus: from cellular organization to function. Neuron. 2017;94(1):7–18.
   PubMed Web of Science ®Google Scholar
• Stockbridge MD, Keser Z, Bunker LD, et al. No evidence of impediment by three common classes of prescription drugs to post-stroke aphasia recovery in a retrospective longitudinal sample. PLoS ONE. 2022;17(6):e0270135.
   PubMed Web of Science ®Google Scholar
• Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol. 1998;55(4):454–456.
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Thompson P, et al. Topiramate and word-finding difficulties in patients with epilepsy. Neurology. 2003;60(7):1104–1107.
   PubMed Web of Science ®Google Scholar
• Cappa SF, Ortelli P, Garibotto V, et al. Reversible nonfluent aphasia and left frontal hypoperfusion during topiramate treatment. Epilepsy Behav. 2007;10(1):192–194.
   PubMed Web of Science ®Google Scholar
• Wong ICK, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf. 2000;23(1):35–56.
   PubMed Web of Science ®Google Scholar
• Wandschneider B, Koepp MJ. Pharmaco fMRI: determining the functional anatomy of the effects of medication. NeuroImage Clin. 2016;12:691–697.
   PubMed Web of Science ®Google Scholar
• Wandschneider B, Burdett J, Townsend L, et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology. 2017;88(12):1165–1171. doi: 10.1212/WNL.0000000000003736
   PubMed Web of Science ®Google Scholar
• Albert ML. Treatment of aphasia. Arch Neurol. 1998;55(11):1417–1419.
   PubMedGoogle Scholar
• Hughes JD, Jacobs DH, Heilman KM. Neuropharmacology and linguistic neuroplasticity. Brain Lang. 2000;71(1):96–101.
   PubMed Web of Science ®Google Scholar
• Roberts S, Bruce RM, Lim L, et al. Better long-term speech outcomes in stroke survivors who received early clinical speech and language therapy: what’s driving recovery? Neuropsychol Rehabil. 2022;32(9):2319–2341. doi: 10.1080/09602011.2021.1944883
   PubMed Web of Science ®Google Scholar
• Price CJ, Seghier ML, Leff AP. Predicting language outcome and recovery after stroke: the PLORAS system. Nat Rev Neurol. 2010;6(4):202–210.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Benson DF. Depression in aphasic patients: frequency, severity, and clinical-pathological correlations. Brain Lang. 1981;14(2):282–291.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Robinson RG. Aphasia and depression. Aphasiology. 1988;2(1):1–19.
   Google Scholar
• Edelkraut L, López-Barroso D, Torres-Prioris MJ, et al. Spectrum of neuropsychiatric symptoms in chronic post-stroke aphasia. World J Psychiatry. 2022;12(3):450–469. doi: 10.5498/WJP.V12.I3.450
   PubMed Web of Science ®Google Scholar
• Watila MM, Balarabe SA. Factors predicting post-stroke aphasia recovery. J Neurol Sci. 2015;352(1–2):12–18.
   PubMed Web of Science ®Google Scholar
• Johnson L, Nemati S, Bonilha L, et al. Predictors beyond the lesion: health and demographic factors associated with aphasia severity. Cortex. 2022;154:375–389.
   PubMed Web of Science ®Google Scholar
• Wang L, Conner JM, Nagahara AH, et al. Rehabilitation drives enhancement of neuronal structure in functionally relevant neuronal subsets. Proc Natl Acad Sci U S A. 2016;113(10):2750–2755.
   PubMed Web of Science ®Google Scholar
• Kilgard MP, Merzenich MM. Cortical map reorganization enabled by nucleus basalis activity. Science. 1998;279(5357):1714–1718.
   PubMed Web of Science ®Google Scholar
• Berthier ML, Dávila G, López-Barroso D, et al. 2020.Pharmacological treatment of post-stroke cognitive deficits; In: Lazar R, Pavol M, and Browndyke J, editors. Neurovascular Neuropsychology. Second. Springer Science + Business Media. Behavioral Sciences: (NY), p. 465–500. doi: 10.1007/978-3-030-49586-2_19
   Google Scholar
• Kim JO, Lee SJ, Pyo JS, et al. Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: a meta-analysis. PLoS ONE. 2020;15(2):e0227820.
   PubMed Web of Science ®Google Scholar
• Berthier ML, Hinojosa J, Del C MM, et al. Open-label study of donepezil in chronic poststroke aphasia. Neurology. 2003;60(7):1218–1219.
   PubMed Web of Science ®Google Scholar
• Berthier ML, Green C, Higueras C, et al. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology. 2006;67(9):1687–1689. doi: 10.1212/01.WNL.0000242626.69666.E2
   PubMed Web of Science ®Google Scholar
• Ying C, Li Y-S, Wang Z-Y, et al. [The efficacy of donepezil for post-stroke aphasia: a pilot case control study.]. Zhonghua Nei Ke Za Zhi. 2010;49(2):115–118.
   PubMedGoogle Scholar
• Hong JM, Shin DH, Lim TS, et al. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry. 2012;83(7):675–680. doi: 10.1136/JNNP-2012-302268
   PubMed Web of Science ®Google Scholar
• Nitrini R, Lucato LT, Sitta MC, et al. Preserved repetition in thalamic afasia. A pathophysiological hypothesis. Dement Neuropsychol. 2019;13(2):244–249. doi: 10.1590/1980-57642018DN13-020015
   PubMedGoogle Scholar
• Berthier ML, Santana-Moreno D, Beltrán-Corbellini Á, et al. Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia. Aphasiology. 2022;36(11):1293–1311. doi: 10.1080/02687038.2021.1957082
   Web of Science ®Google Scholar
• Berthier ML, Pulvermüller F, Dávila G, et al. Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol rev. 2011;21(3):302–317. doi: 10.1007/s11065-011-9177-7
   PubMed Web of Science ®Google Scholar
• Woodhead ZVJ, Crinion J, Teki S, et al. Auditory training changes temporal lobe connectivity in ‘Wernicke’s aphasia’: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88(7):586–594. doi: 10.1136/JNNP-2016-314621
   PubMed Web of Science ®Google Scholar
• Walker-Batson D, Mehta J, Smith P, et al. Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke. Prog Neuropsychopharmacol Biol Psychiatry. 2016:64;225–230. doi: 10.1016/J.PNPBP.2015.04.002
   PubMed Web of Science ®Google Scholar
• Zhang J, Wei R, Chen Z, et al. Piracetam for aphasia in post-stroke patients: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(7):575–587.
   PubMed Web of Science ®Google Scholar
• Güngör L, Terzi M, Onar MK. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases? Brain Lang. 2011;117(1):23–27.
   PubMed Web of Science ®Google Scholar
• Malík M, Tlustoš P. Nootropics as cognitive enhancers: types, dosage and side effects of smart drugs. Nutrients. 2022;14(16):3367.
   PubMed Web of Science ®Google Scholar
• Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287–312.
   PubMed Web of Science ®Google Scholar
• Li W, Kutas M, Gray JA, et al. The Role of Glutamate in Language and Language Disorders - Evidence from ERP and Pharmacologic Studies. Neurosci Biobehav Rev. 2020;119:217–241.
   PubMed Web of Science ®Google Scholar
• Ocklenburg S, Arning L, Hahn C, et al. Variation in the NMDA receptor 2B subunit gene GRIN2B is associated with differential language lateralization. Behav Brain Res. 2011;225(1):284–289. doi:10.1016/J.BBR.2011.07.042
   PubMed Web of Science ®Google Scholar
• Barbancho MA, Berthier ML, Navas-Sánchez P, et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: an ERP study. Brain Lang. 2015;145–146:1–10.
   PubMed Web of Science ®Google Scholar
• Gill SK, Leff AP. Dopaminergic therapy in aphasia. Aphasiology. 2012;28(2):155–170.
   PubMed Web of Science ®Google Scholar
• Stockbridge MD. Better language through chemistry: augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia. Handb Clin Neurol. 2022;185:261–272. doi: 10.1016/B978-0-12-823384-9.00013-X
   PubMedGoogle Scholar
• Galling MA, Goorah N, Berthier ML, et al. A clinical study of the combined use of bromocriptine and speech and language therapy in the treatment of a person with aphasia. Aphasiology. 2014;28(2):171–187.
   Web of Science ®Google Scholar
• Berthier ML. Transcortical Aphasias. London: Psychology Press; 1999.
   Google Scholar
• Tan LCS, KKC N, Au WL, et al. Bromocriptine use and the risk of valvular heart disease. Mov Disord. 2009;24(3):344–349. doi: 10.1002/MDS.22228
   PubMed Web of Science ®Google Scholar
• Leiguarda R, Merello M, Sabe L, et al. Bromocriptine-induced dystonia in patients with aphasia and hemiparesis. Neurology. 1993;43(11):2319–2319.
   PubMed Web of Science ®Google Scholar
• Knecht S, Breitenstein C, Bushuven S, et al. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004;56(1):20–26. doi: 10.1002/ana.20125
   PubMed Web of Science ®Google Scholar
• Seniów J, Litwin M, Litwin T, et al. New approach to the rehabilitation of post-stroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J Neurol Sci. 2009;283(1–2):214–218. doi: 10.1016/J.JNS.2009.02.336
   PubMed Web of Science ®Google Scholar
• Breitenstein C, Korsukewitz C, Baumgärtner A, et al. L-dopa does not add to the success of high-intensity language training in aphasia. Restor Neurol Neurosci. 2015;33(2):115–120. doi: 10.3233/RNN-140435
   PubMed Web of Science ®Google Scholar
• Gorgoraptis N, Mah YH, MacHner B, et al. The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke. Brain. 2012;135(8):2478–2491. doi: 10.1093/BRAIN/AWS154
   PubMedGoogle Scholar
• Cahana-Amitay D, Albert ML, Pyun SB, et al. Language as a Stressor in Aphasia. Aphasiology. 2011;25(5):593–614. doi: 10.1080/02687038.2010.541469
   PubMed Web of Science ®Google Scholar
• Torres-Prioris MJ, López-Barroso D, Paredes-Pacheco J, et al. Language as a threat: multimodal evaluation and interventions for overwhelming linguistic anxiety in severe aphasia. Front Psychol. 2019;10. doi: 10.3389/fpsyg.2019.00678
   PubMed Web of Science ®Google Scholar
• Raymer AM. Treatment of adynamia in aphasia. Front Biosci. 2003;8(6):s845–851.
   PubMedGoogle Scholar
• Walker-Batson D, Curtis S, Natarajan R, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001;32(9):2093–2098. doi: 10.1161/HS0901.095720
   PubMed Web of Science ®Google Scholar
• Keser Z, Dehgan MW, Shadravan S, et al. Combined Dextroamphetamine and Transcranial Direct Current Stimulation in Poststroke Aphasia. Am J Phys Med Rehabil. 2017;96(10):S141–S145. doi: 10.1097/PHM.0000000000000780
   PubMed Web of Science ®Google Scholar
• Worrall LE, Hudson K, Khan A, et al. Determinants of living well with aphasia in the first year poststroke: a prospective cohort study. Arch Phys Med Rehabil. 2017;98(2):235–240. doi: 10.1016/J.APMR.2016.06.020
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Albert M (2004) Serotonergic therapy shows promise for aphasia. In: Neurology Today. https://journals.lww.com/neurotodayonline/Fulltext/2004/06000/SEROTONERGIC_THERAPY_SHOWS_PROMISE_FOR_APHASIA.17.aspx. Accessed 22 Oct 2020
   Google Scholar
• Hillis AE, Beh YY, Sebastian R, et al. Predicting recovery in acute poststroke aphasia. Ann Neurol. 2018;83(3):612–622. doi: 10.1002/ana.25184
   PubMed Web of Science ®Google Scholar
• Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900–909. doi: 10.1176/AJP.2007.164.6.900
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Reinlieb M, Cyr NS, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561–569. doi: 10.1176/APPI.AJP.2014.14070889
   PubMed Web of Science ®Google Scholar
• Blumberg MJ, Vaccarino SR, McInerney SJ. Procognitive effects of antidepressants and other therapeutic agents in major depressive disorder: a systematic review. J Clin Psychiatry. 2020;81(4). doi: 10.4088/JCP.19R13200
   PubMed Web of Science ®Google Scholar
• Mortensen JK, Andersen G. Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance. Expert Opin Pharmacother. 2021;22(9):1157–1166.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157(3):351–359. doi: 10.1176/APPI.AJP.157.3.351
   PubMed Web of Science ®Google Scholar
• Sunami E, Usuda K, Nishiyama Y, et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med. 2012;51(10):1187–1193. doi: 10.2169/INTERNALMEDICINE.51.6699
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Hayhow BD. Treatment of post-stroke depression. Curr Treat Options Neurol. 2019;21(7). doi: 10.1007/S11940-019-0570-5
   PubMed Web of Science ®Google Scholar
• Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67(2):187–196. doi: 10.1001/ARCHGENPSYCHIATRY.2009.185
   PubMed Web of Science ®Google Scholar
• Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–130. doi: 10.1016/S1474-4422(10)70314-8
   PubMed Web of Science ®Google Scholar
• Laino C. Serotonergic therapy shows promise for aphasia. Neurology Today. 2004;4(6):54–54.
   Google Scholar
• Robinson RG, Jorge RE. Prevention of first-episode depression: progress and potential. Br J Psychiatry. 2009;194(4):296–297.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391–2400.
   PubMed Web of Science ®Google Scholar
• Stockbridge MD, Fridriksson J, Sen S, et al. Protocol for escitalopram and language intervention for subacute aphasia (ELISA): a randomized, double blind, placebo-controlled trial. PLoS ONE. 2021;16(12):e0261474. doi: 10.1371/JOURNAL.PONE.0261474
   PubMed Web of Science ®Google Scholar
• Chen G, Højer AM, Areberg J, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686.
   PubMed Web of Science ®Google Scholar
• Conen S, McKie S, Smallman RP, et al. P.2.F.014 Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls. Eur Neuropsychopharmacol. 2015;25:S442.
   Web of Science ®Google Scholar
• Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother. 2017;18(10):1011–1017.
   PubMed Web of Science ®Google Scholar
• Cramer SC; Cramer SC. Repairing the human brain after stroke. II. restorative therapies. Ann Neurol. 2008;63(5):549–560. doi:10.1002/ana.21412
   PubMed Web of Science ®Google Scholar
• Berthier ML, Pulvermüller F. Neuroscience insights improve neurorehabilitation of poststroke aphasia. Nat Rev Neurol. 2011;7(2):86–97.
   PubMed Web of Science ®Google Scholar
• Basso A, Macis M. Therapy efficacy in chronic aphasia. Behav Neurol. 2011;24(4):317–325.
   PubMed Web of Science ®Google Scholar
• López-Barroso D, Torres-Prioris MJ, Beltrán-Corbellini Á, et al. Beneficial effects of pharmacological treatment in post-stroke dynamic aphasia: a behavioural and neuroimaging study. In: .Bresanonne, Italy:European Workshop for Cognitive Neuropsychology; 2018. https://hdl.handle.net/10630/15168
   Google Scholar
• Tocco M, Bayles K, Lopez OL, et al. Effects of memantine treatment on language abilities and functional communication: a review of data. Aphasiology. 2014;28(2):236–257. doi: 10.1080/02687038.2013.838617
   Web of Science ®Google Scholar
• McNamara P, Albert ML. Neuropharmacology of verbal perseveration. Semin Speech Lang. 2004;25(4):309–321.
   PubMedGoogle Scholar
• Tanaka Y, Albert ML, Fujita K, et al. Treating perseveration improves naming in aphasia. Brain Lang. 2006;99(1–2):57–58. doi: 10.1016/J.BANDL.2006.06.038
   Web of Science ®Google Scholar
• Berthier ML, Torres-Prioris MJ, López-Barroso D, et al. Are you a doctor? … are you a doctor? I’m not a doctor! A reappraisal of mitigated echolalia in aphasia with evaluation of neural correlates and treatment approaches. Aphasiology. 2018;32(7):784–813. doi: 10.1080/02687038.2016.1274875
   Web of Science ®Google Scholar
• Torres-Prioris MJ, López-Barroso D, Roé-Vellvé N, et al. Repetitive verbal behaviors are not always harmful signs: compensatory plasticity within the language network in aphasia. Brain Lang. 2019;190:16–30.
   PubMed Web of Science ®Google Scholar
• Kristinsson S, Busby N, Rorden C, et al. Brain age predicts long-term recovery in post-stroke aphasia. Brain Commun. 2022;4(5).
   PubMedGoogle Scholar
• García RR, Montiel JF, Villalón AU, et al. AChE-rich magnopyramidal neurons have a left–right size asymmetry in Broca’s area. Brain Res. 2004;1026(2):313–316. doi: 10.1016/J.BRAINRES.2004.08.050
   PubMed Web of Science ®Google Scholar
• Hutsler JJ, Gazzaniga MS. Acetylcholinesterase staining in human auditory and language cortices: regional variation of structural features. Cereb Cortex. 1996;6(2):260–270.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Miyazaki M, Albert ML. Effects of increased cholinergic activity on naming in aphasia. Lancet. 1997;350(9071):116–117.
   PubMed Web of Science ®Google Scholar
• Robb MA, McInnes PM, Califf RM. Biomarkers and Surrogate endpoints: developing common terminology and definitions. JAMA. 2016;315:1107–1108.
   PubMed Web of Science ®Google Scholar
• Meinzer M, Darkow R, Lindenberg R, et al. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain. 2016;139(4):1152–1163.
   PubMed Web of Science ®Google Scholar